10-Q: H.B. Fuller Reports Strong Q3 Earnings Growth

H.B. Fuller Company announced a significant increase in third-quarter net revenue and net income, driven by higher pricing and strategic acquisitions.

Summary

• H.B. Fuller reported a 5.2% increase in net revenue for Q3 2026 to $938.2 million, and a 3.1% increase for the nine-month period to $2,659.3 million.
• Net income attributable to H.B. Fuller rose 17.9% to $79.2 million in Q3 2026, with diluted EPS at $1.44, up from $1.22 in Q3 2025.
• For the nine-month period, net income increased 37.6% to $168.0 million, with diluted EPS at $3.05, up from $2.21.
• Gross profit margin improved by 120 basis points in Q3 and 160 basis points year-to-date, attributed to higher pricing and restructuring actions.
• Adjusted EBITDA increased by 9.4% in Q3 to $186.7 million and by 8.0% year-to-date to $486.5 million.
• The company completed several acquisitions, including Dongguan Nako, ND Industries Turkey, ND Industries Taiwan, GEM, and Medifill, to drive growth in high-margin segments.
• Restructuring plans are ongoing, with expected costs of $87-$90 million for organizational changes and $45-$50 million for global footprint optimization.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue and net income growth, improved margins, and effective management of acquisitions and restructuring.

Positives

• Net revenue increased by 5.2% to $938.2 million in Q3 2026 and by 3.1% to $2,659.3 million for the nine months ended August 29, 2026.
• Net income attributable to H.B. Fuller increased by 17.9% to $79.2 million in Q3 2026 and by 37.6% to $168.0 million for the nine-month period.
• Diluted earnings per share improved to $1.44 in Q3 2026 from $1.22 in Q3 2025, and to $3.05 from $2.21 for the nine-month period.
• Gross profit margin expanded by 120 basis points in Q3 and 160 basis points year-to-date, driven by higher product pricing and restructuring.
• Adjusted EBITDA grew by 9.4% in Q3 and 8.0% year-to-date, indicating strong operational performance.
• Strategic acquisitions in key growth markets (e.g., Dongguan Nako, ND Industries Turkey, GEM, Medifill) are contributing to revenue and portfolio enhancement.
• The company is actively managing restructuring initiatives, which are expected to yield future efficiencies.

Negatives

• Sales volume decreased by 3.0% in Q3 2026 and by 3.3% year-to-date, indicating a decline in unit sales.
• Selling, general, and administrative (SG&A) expenses increased by 13.4% in Q3 and 8.0% year-to-date, impacting profitability margins.
• Interest expense increased by 21.7% in Q3 and 6.0% year-to-date, primarily due to higher debt levels and extinguishment costs.
• Inventory days on hand increased to 88 days from 78 days year-over-year, suggesting potential inefficiencies in inventory management.
• Free cash flow decreased to $40.9 million in the nine-month period of 2026 from $62.2 million in the same period of 2025.

Risks

• Shareholder activism efforts, such as the unsolicited acquisition proposal for the Building Adhesive Solutions segment by Ancora Holdings Group, could be disruptive and costly.
• The pending acquisition of Advanced Medical Solutions Group plc (AMS) is subject to regulatory approvals and other customary closing conditions.
• Ongoing restructuring plans are expected to incur significant costs, with the majority of charges and cash payments occurring in fiscal years 2026 and 2027.
• Environmental investigations and potential liabilities related to former and current operating facilities require ongoing monitoring and management.
• Asbestos litigation continues, with a proposed settlement in Rouse et al. v. H.B. Fuller Company et al. for up to $75.0 million, though insurance reimbursement is being pursued.

Future Outlook

The company is pursuing a pending acquisition of Advanced Medical Solutions Group plc (AMS), expected to close by year-end, subject to regulatory approvals. Restructuring actions are ongoing and expected to be completed by fiscal year 2028, with the majority of charges and cash payments anticipated in fiscal 2026 and 2027.

Management Comments

• The acquisition of Dongguan Nako is expected to accelerate the realization of top growth priorities in China, consistent with the strategy to proactively drive capital allocation to the highest margin, highest growth market segments.
• The acquisition of ND Industries Turkey is expected to accelerate the realization of top growth priorities in EIMEA, consistent with the strategy to proactively drive capital allocation to the highest margin, highest growth market segments.
• The acquisitions of GEM and Medifill established a European headquarters for the Medical Adhesives Technologies business and European production capabilities, further shifting the portfolio toward highly profitable, higher growth markets.
• The company believes that cash flows from operating activities will be adequate to meet its short-term and long-term liquidity and capital expenditure needs and has the ability to obtain both short-term and long-term debt.
• The Board of Directors unanimously determined to reject Ancora Holdings Group's unsolicited proposal to acquire the Building Adhesive Solutions segment because it materially undervalued the business.

Industry Context

StockSavvy.ai notes that H.B. Fuller's performance aligns with broader industry trends of consolidation and strategic acquisitions aimed at capturing higher-margin segments. The company's focus on specialized adhesives and coatings, particularly in medical and engineering applications, positions it to benefit from these market shifts.

Comparison to Industry Standards

• H.B. Fuller's revenue growth of 5.2% in Q3 2026 and 3.1% year-to-date is generally in line with or slightly above the specialty chemicals sector, which has seen moderate growth driven by pricing power.
• The improvement in gross profit margin (120 bps in Q3, 160 bps YTD) reflects successful price increases, a common strategy across the industry to offset raw material cost pressures.
• The company's Adjusted EBITDA margin of 19.9% in Q3 2026 is competitive within the adhesives and sealants industry, though specific benchmarks vary by sub-segment.
• The decline in sales volume (3.0% in Q3, 3.3% YTD) is a concern shared by some industry players facing softer demand in certain end markets, though pricing power has mitigated the impact on revenue.
• The company's strategic acquisitions, such as AMS, align with industry consolidation trends, where larger players acquire specialized capabilities to enhance their market position and product portfolios.

Legal Proceedings

• Environmental investigations, clean-up activities, and administrative proceedings related to environmental compliance matters at former and current operating facilities.
• Identification as a potentially responsible party (PRP) under CERCLA and similar state laws for costs relating to contamination.
• Lawsuits alleging injury due to products containing asbestos manufactured over 35 years ago.
• Rouse et al. v. H.B. Fuller Company et al. lawsuit seeking damages for property damage attributed to alleged defects in grout sold by the company's divested North America Flooring business, with a proposed settlement of up to $75.0 million.

Stakeholder Impact

• Shareholders may be impacted by shareholder activism efforts, such as the unsolicited acquisition proposal for the Building Adhesive Solutions segment, which could create uncertainty and volatility.
• Employees may be affected by ongoing restructuring plans, which involve severance and other employee costs.
• Customers may benefit from the company's strategic acquisitions aimed at enhancing product offerings and market presence.
• Suppliers' payment obligations are not impacted by the supplier finance program, but the program facilitates their ability to finance these obligations.

Next Steps

• Complete the acquisition of Advanced Medical Solutions Group plc (AMS) by the end of the calendar year, subject to regulatory approvals.
• Continue to implement restructuring plans, with the majority of charges and cash payments expected in fiscal years 2026 and 2027.
• Continue to optimize global footprint through restructuring actions expected to be completed by fiscal year 2028.
• Pursue reimbursement from insurers for a substantial portion of the potential settlement amount in the Rouse et al. v. H.B. Fuller Company et al. litigation.

Key Dates

Recommendation

The company demonstrates strong operational performance with revenue and profit growth, driven by pricing power and strategic acquisitions. However, the decrease in sales volume, increase in SG&A expenses, and ongoing restructuring costs present headwinds. The pending acquisition of AMS is a significant event that requires further evaluation of its integration and financial impact. While the results are positive, the existing risks and the need to digest recent acquisitions warrant a 'hold' recommendation pending clearer visibility on future volume trends and acquisition integration.

Keywords

adhesives, sealants, coatings, Hygiene Health Consumable Adhesives, Engineering Adhesives, Building Adhesive Solutions, acquisitions, restructuring